Kenneth J Pienta MD

Oncology•Baltimore, MD

Genitourinary Oncology, Hematologic Oncology

Professor, Johns Hopkins University

Join to View Full Profile

201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Summary

Dr. Kenneth Pienta, based in Baltimore, MD, is a distinguished oncologist specializing in genitourinary and hematologic oncology. He completed his medical education at the Johns Hopkins University School of Medicine, followed by residency in internal medicine at the University of Chicago and a fellowship in hematology and medical oncology at Johns Hopkins. Currently, he is a professor at Johns Hopkins University School of Medicine. Dr. Pienta has extensive experience with prostate cancer, urologic oncology, and related diagnostic techniques, such as immunohistochemistry and flow cytometry. He has contributed significantly to academic literature, with several recent publications in various medical journals. Outside academics, he has led multiple clinical trials focusing on innovative treatments for prostate cancer. Recognized among the top doctors in America, Dr. Pienta has received numerous accolades for his contributions to the field of oncology.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1986 - 1988
Johns Hopkins University School of MedicineClass of 1986

Certifications & Licensure

NY State Medical License 1987 - Present
MD State Medical License 1988 - 2025
MI State Medical License 1991 - 2025
IL State Medical License 1986 - 1989
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2020
America's Top Doctors for Cancer Castle Connolly, 2005-2020
Top Doctors:Baltimore Area Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Elected Member The American Society for Clinical Investigation, 2005
Join now to see all

Clinical Trials

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 3
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 3
S0916, MLN1202 in Treating Patients With Bone Metastases Start of enrollment: 2010 Mar 01
Completed
Phase 2
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance Start of enrollment: 2014 Mar 01
Withdrawn
Phase 2
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Start of enrollment: 2014 Sep 01
Withdrawn
Phase 2
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer Start of enrollment: 2016 Jul 01
Terminated
Phase 1
A Study of Definitive Therapy to Treat Prostate Cancer Start of enrollment: 2016 Jun 01
Completed
Phase 2
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance Start of enrollment: 2017 Nov 02
Terminated
Phase 2
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer Start of enrollment: 2016 Nov 01
Completed
Phase 2, Phase 3
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy Start of enrollment: 2017 Feb 22
Completed
Phase 2
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer Start of enrollment: 2019 Aug 28
Terminated
Phase 2
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Start of enrollment: 2024 Jan 01
Withdrawn
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Temporal myc dynamics permit mitotic bypass, promoting polyploid phenotypes.
Michael A Loycano, Kenneth J Pienta, Sarah R Amend
Cancer Letters. 2025-03-31
Correction to: Urinary extracellular vesicle‑derived miR‑126‑3p predicts lymph node invasion in patients with high‑risk prostate cancer.
Liang Dong, Cong Hu, Zehua Ma, Yiyao Huang, Greg Shelley
Medical Oncology. 2025-03-21
Benthic diel oxygen variability and stress as potential drivers for animal diversification in the Neoproterozoic-Palaeozoic.
Emma U Hammarlund, Anuraag Bukkuri, Magnus D Norling, Mazharul Islam, Nicole R Posth
Nature Communications. 2025-03-21

Journal Articles

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Prostate-Specific Markers to Identify Rare Prostate Cancer Cells in Liquid Biopsies
Kenneth Pienta, MD, Nature
Cooperation Among Cancer Cells: Applying Game Theory to Cancer
Kenneth Pienta, MD, Nature
Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting
Thomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Join now to see all

Press Mentions

The Prostate Cancer Foundation Announces 2020 Challenge Awards Totaling More Than $11 Million for Prostate Cancer ResearchDecember 31st, 2020
A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles RyanSeptember 24th, 2020
Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem EngineersMarch 4th, 2020
Join now to see all

Grant Support

Prostate Cancer Induces CCL2 Expression And Transforms The Bone MicroenviNational Cancer Institute2009–2012
Mechanisms Of Prostate Cancer Dormancy In The Bone Marrow NicheNational Cancer Institute2011
Reactive Stroma And Tumor Associated Macrophages In Prostate Cancer ProgressionNational Cancer Institute2010–2011
Carryover From Year -09 For Phase II Evaluation Of EMD 12194National Cancer Institute2008–2011
Administration CoreNational Cancer Institute2008–2011
Spore In Prostate CancerNational Cancer Institute1995–2011
Annual Meeting For The Clinical Research Ethics Key Function CommitteeNational Center For Research Resources2010
CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2009–2010
CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2009–2010
CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2009–2010
Michigan Institute For Clinical And Health Research (MICHR) (UL1)National Center For Research Resources2008–2010
Michigan Institute For Clinical And Health Research (MICHR) (Ul1): (BPCA)National Center For Research Resources2009
Michigan Institute For Clinical And Health Research (MICHR) (TL1)National Center For Research Resources2008–2009
Michigan Institute For Clinical And Health Research (MICHR) (KL2)National Center For Research Resources2008–2009
The Therapeutic Potential, Pharmacology And Toxiciity Of Promising Small-MoleculeNational Cancer Institute2005–2009
PAR1 In Prostate Cancer Cell Motility And InvasionNational Cancer Institute2004–2008
S.P.O.R.E. In Prostate CancerNational Cancer Institute2003–2007
Molecular Changes Associated With PCA Bone MetastasesNational Cancer Institute2003–2006
Urology Research Training GrantNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2004
Pilot--Prostate Cancer And Urological OncologyNational Cancer Institute2001–2002
Inhibition Of Human Prostate Cancer MetastasisNational Cancer Institute1998–2002
Developmental Research ProgramNational Cancer Institute1998–2002
Prostate Cancer Metastasis To BoneNational Cancer Institute1999–2000
Nuclear Matrix As A Target For Prostate Cancer ChemotherapyNational Center For Research Resources1998–1999
Phase II Clinical Trials Of New Chemopreventive AgentsDivision Of Cancer Prevention And Control1998
Aminocamptothecin (9 Ac/Dma) In Hormone Refractory Prostate CancerNational Center For Research Resources1997
Inhibition Of Human Prostate-Cancer Metastasis By Modified Citrus PectinNational Cancer Institute1996–1997
Emcyt, VP16, And Taxol For Metastatic Prostate CancerNational Cancer Institute1996–1997
Organization Of DNA In Cancer CellsNational Cancer Institute1994–1996
Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1994
The Organization Of DNA In Cancer CellsNational Cancer Institute1993
Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1992–1993
Organization Of DNA In Cancer CellsNational Cancer Institute1992